GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eagle Pharmaceuticals Inc (NAS:EGRX) » Definitions » Beneish M-Score

Eagle Pharmaceuticals (Eagle Pharmaceuticals) Beneish M-Score : -1.90 (As of Apr. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Eagle Pharmaceuticals Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -1.9 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Eagle Pharmaceuticals's Beneish M-Score or its related term are showing as below:

EGRX' s Beneish M-Score Range Over the Past 10 Years
Min: -4.15   Med: -2.38   Max: 166.33
Current: -1.9

During the past 11 years, the highest Beneish M-Score of Eagle Pharmaceuticals was 166.33. The lowest was -4.15. And the median was -2.38.


Eagle Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for Eagle Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eagle Pharmaceuticals Beneish M-Score Chart

Eagle Pharmaceuticals Annual Data
Trend Sep13 Sep14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.39 -3.56 -2.90 -3.24 -1.63

Eagle Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.76 -1.29 -1.63 -2.49 -1.90

Competitive Comparison of Eagle Pharmaceuticals's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Eagle Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eagle Pharmaceuticals's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eagle Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Eagle Pharmaceuticals's Beneish M-Score falls into.



Eagle Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Eagle Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.3203+0.528 * 1.0531+0.404 * 1.0989+0.892 * 0.9462+0.115 * 0.7928
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1152+4.679 * 0.067412-0.327 * 1.0059
=-1.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun23) TTM:Last Year (Jun22) TTM:
Total Receivables was $116.3 Mil.
Revenue was 64.646 + 66.305 + 60.699 + 65.901 = $257.6 Mil.
Gross Profit was 47.788 + 49.005 + 40.833 + 42.25 = $179.9 Mil.
Total Current Assets was $187.3 Mil.
Total Assets was $404.8 Mil.
Property, Plant and Equipment(Net PPE) was $1.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $20.6 Mil.
Selling, General, & Admin. Expense(SGA) was $103.2 Mil.
Total Current Liabilities was $86.6 Mil.
Long-Term Debt & Capital Lease Obligation was $61.9 Mil.
Net Income was 5.164 + 5.75 + 8.165 + -7.131 = $11.9 Mil.
Non Operating Income was 0.247 + -0.238 + 5.501 + -11.534 = $-6.0 Mil.
Cash Flow from Operations was -0.126 + -33.512 + 37.557 + -13.237 = $-9.3 Mil.
Total Receivables was $93.1 Mil.
Revenue was 74.136 + 115.874 + 42.32 + 39.853 = $272.2 Mil.
Gross Profit was 50.472 + 88.119 + 30.011 + 31.594 = $200.2 Mil.
Total Current Assets was $194.5 Mil.
Total Assets was $381.8 Mil.
Property, Plant and Equipment(Net PPE) was $1.5 Mil.
Depreciation, Depletion and Amortization(DDA) was $4.5 Mil.
Selling, General, & Admin. Expense(SGA) was $97.8 Mil.
Total Current Liabilities was $109.0 Mil.
Long-Term Debt & Capital Lease Obligation was $30.3 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(116.284 / 257.551) / (93.081 / 272.183)
=0.451499 / 0.341979
=1.3203

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(200.196 / 272.183) / (179.876 / 257.551)
=0.73552 / 0.698409
=1.0531

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (187.25 + 1.013) / 404.822) / (1 - (194.456 + 1.459) / 381.756)
=0.534949 / 0.486806
=1.0989

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=257.551 / 272.183
=0.9462

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(4.512 / (4.512 + 1.459)) / (20.622 / (20.622 + 1.013))
=0.755652 / 0.953178
=0.7928

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(103.223 / 257.551) / (97.821 / 272.183)
=0.400787 / 0.359394
=1.1152

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((61.896 + 86.63) / 404.822) / ((30.274 + 108.964) / 381.756)
=0.366892 / 0.36473
=1.0059

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(11.948 - -6.024 - -9.318) / 404.822
=0.067412

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Eagle Pharmaceuticals has a M-score of -1.90 suggests that the company is unlikely to be a manipulator.


Eagle Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Eagle Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Eagle Pharmaceuticals (Eagle Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ, USA, 07677
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.
Executives
Scott Tarriff director, officer: President and CEO 28 TUDOR ROSE TERRACE, MAHWAH NJ 07430
Richard A. Edlin director C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Michael Shawn Moran officer: EVP, Chief Commercial Officer C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF NJ 07677
Luciana Borio director C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677
Brian Joseph Cahill officer: Chief Financial Officer C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Judith Ng-cashin officer: Chief Medical Officer C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Hudson Executive Capital Lp director C/O CADWALADER, WICKERSHAM & TAFT, LLP, 200 LIBERTY STREET, NEW YORK NY 10281
Hec Management Gp Llc director 1185 AVENUE OF THE AMERICAS, 32ND FLOOR, NEW YORK NY 10036
Jennifer K. Simpson director C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Douglas L Braunstein director HUDSON EXECUTIVE CAPITAL LP, 570 LEXINGTON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Sander A Flaum director 630 PARK AVE, NEW YORK NY 10019
Pete A. Meyers officer: Chief Financial Officer C/O TETRALOGIC PHARMACEUTICALS CORP, 343 PHOENIXVILLE PIKE, MALVERN PA 19355
David Pernock director 405 EAGLEVIEW BOULEVARD, EXTON PA 19341
Proquest Investments Iv, L.p. 10 percent owner 2430 VANDERBILT BEACH ROAD, #108 - 190, NAPLES FL 34109
Steven L. Krill officer: Chief Scientific Officer C/O EAGLE PHARMCEUTICALS, INC., 50 TICE BLVD. SUITE 315, WOODCLIFF LAKE NJ 07677

Eagle Pharmaceuticals (Eagle Pharmaceuticals) Headlines

From GuruFocus